Septerna (SEPN) Corporate presentation summary

Strategic focus and platform innovation

• Native Complex Platform enables rapid, structure-based drug design for difficult-to-drug GPCRs, supporting a broad pipeline of oral small molecule therapies targeting significant unmet needs.

• Platform has delivered >150 high-resolution cryo-EM GPCR structures, accelerating lead optimization and candidate selection.

• Portfolio strategy emphasizes validated targets, early clinical readouts, and multi-billion dollar market opportunities.

• Cash runway is projected to support operations at least into 2029.

Lead programs and clinical development

• SEP-479, a PTH1R agonist for hypoparathyroidism, is on track for Phase 1 initiation in 1H 2026, with topline data expected late 2026/early 2027.

• SEP-479 demonstrated potent, selective, oral activity, normalizing serum calcium and phosphate in animal models, with favorable PK and safety profiles.

• SEP-631, an MRGPRX2 NAM for mast cell-driven diseases (e.g., CSU), is in Phase 1 with SAD/MAD results to be presented in March 2026.

• SEP-631 showed high potency, broad inhibition, and excellent oral bioavailability in preclinical models, with ongoing long-term toxicology studies.

• TSHR NAM program targets Graves' disease and TED, with preclinical leads reversing disease symptoms in animal models and ongoing optimization.

Partnered and discovery-stage programs

• Collaboration with Novo Nordisk covers oral small molecules for metabolic diseases, including GLP-1, GIP, and glucagon receptors.

• Novo Nordisk partnership includes $195M upfront, up to ~$500M in milestones per program, and tiered royalties, with Novo covering all R&D expenses.

• Multiple lead compounds for TSHR and incretin receptor agonists are advancing toward development candidate selection.